Taysha Gene Therapies (TSHA) Interest Expenses (2020 - 2026)

Taysha Gene Therapies has reported Interest Expenses for 8 years, with the latest figure at $57.2 million in Q1 2026.

• Quarterly Interest Expenses rose 573.19% year-over-year to $57.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.2 million (up 573.19% YoY) and the FY2025 annual result came in at $81.7 million, down 28.44% from the prior year.
• Interest Expenses advanced to $57.2 million in Q1 2026 per TSHA's latest filing, from $12000.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $57.2 million in Q1 2026 and troughed at $12000.0 in Q4 2025.
• A 5-year average of $14.2 million and a median of $9.6 million in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2023 and 2025: Interest Expenses soared 4226.65% in 2023, then slumped 99.77% in 2025.
• Over 5 years, Interest Expenses stood at $2.0 million in 2022, then slumped by 34.66% to $1.3 million in 2023, then soared by 290.25% to $5.2 million in 2024, then plunged by 99.77% to $12000.0 in 2025, then soared by 476683.33% to $57.2 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $57.2 million, $12000.0, and $31.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.